C08G2650/38

Compound comprising aromatic ring, and polyelectrolyte membrane using same

The present specification relates to a compound comprising an aromatic ring, a polyelectrolyte membrane comprising the same, a membrane-electrode assembly comprising the polyelectrolyte membrane, a fuel cell comprising the membrane-electrode assembly, and a redox flow battery comprising the polyelectrolyte membrane.

Zwitterionic derivatives of (per)fluoropolyethers

(Per)fluoropolyether polymers comprising a (per)fluoropolyether chain having two ends, wherein one or both ends comprise one or more zwitterionic groups at one or both polymer ends, methods for their manufacture and uses thereof are herein disclosed. The polymers can be used in particular for protecting materials in contact with biological fluids or fluids containing biological material from contamination by organic compounds therein contained.

Additive for high-purity copper electrolytic refining and method of producing high-purity copper

The additive for high-purity copper electrolytic refining of the present invention is an additive which is added to a copper electrolyte in electrolytic refining for high-purity copper and is formed of a non-ionic surfactant that includes a hydrophobic group containing an aromatic ring and a hydrophilic group containing a polyoxyalkylene group.

ANTIMICROBIAL POLYMERIC COMPOSITIONS

A compound having the formula:

##STR00001## wherein n, y, R.sub.1 and R.sub.2 are defined herein, and others, methods of making of and using, and compositions made thereby which have an antimicrobial resistance effect are described.

Polyoxymethylene and method of producing same

Polyoxymethylene, where a ratio of a low molecular weight component having a molecular weight of 10,000 or less in a molecular weight distribution is 7.0% or less of the total, and the molecular weight distribution is obtained by measurement by gel permeation chromatography (GPC) using polymethyl methacrylate (PMMA) as a standard substance.

Aqueous polyglycidol synthesis with ultra-low branching
10308763 · 2019-06-04 · ·

Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

CARBONATE-CONTAINING OLIGOMER, MANUFACTURING METHOD THEREOF, AND CROSSLINKED PRODUCT
20240199806 · 2024-06-20 ·

A carbonate-containing oligomer, a manufacturing method for a carbonate-containing oligomer and a crosslinked product are provided. The carbonate-containing oligomer includes a structure represented by formula (I), and formula (I) is defined as in the specification. The crosslinked product is obtained by mixing the carbonate-containing oligomer with a modified polyphenylene ether resin, and adding a peroxide to perform a curing reaction.

OLIGOMER-FOSCARNET CONJUGATES
20190151339 · 2019-05-23 ·

The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.

Process for preparing polymers

A process for preparing non-naturally-occurring defined monomer sequence polymers is provided, and in which a high degree of synthetic control is obtained by the use of solvent resistant diafiltration membranes. Also provided is a process for separating non-naturally-occurring defined monomer sequence polymers from synthetic by-products or excess reagents using solvent resistant diafiltration membranes, and a use of a solvent resistant diafiltration membrane in processes for preparing and separating non-naturally-occurring defined monomer sequence polymers.

Oligomer-foscarnet conjugates
10231984 · 2019-03-19 · ·

The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.